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Abstract
Background: Psychotropic medications have been associated with many adverse outcomes in older people living
in residential care. Home-like models of residential care may be preferable to traditional models of care and we
hypothesized that this model may impact on the prevalence of psychotropic medications. The objectives were to:
1) examine associations between psychotropic medications and quality of life in older adults living in residential
care facilities with a high prevalence of cognitive impairment and dementia and 2) determine if there was a
difference in prevalence of psychotropic medications in facilities which provide a small group home-like model of
residential care compared to a ‘standard model’ of care.
Methods: Participants included 541 residents from 17 residential aged care facilities in the Investigating Services
Provided in the Residential Environment for Dementia (INSPIRED) study. Cross-sectional analyses were completed to
examine the above objectives. Quality of life was measured with the dementia quality of life questionnaire
(DEMQOL) and the EQ-5D-5L completed by the resident or a proxy.
Results: Overall, 70.8% (n = 380) of the population had been prescribed/dispensed at least one psychotropic
medication in the 100 days prior to recruitment. An increased number of psychotropic medications was associated
with lower quality of life according to DEMQOL-Proxy-Utility scores (β (SE): − 0.012 (0.006), p = 0.04) and EQ-5D-5L
scores (− 0.024 (0.011), p = 0.03) after adjustment for resident-level and facility-level characteristics. Analysis of the
individual classes of psychotropic medications showed antipsychotics were associated with lower DEMQOL-Proxy-
Utility scores (− 0.030 (0.014), p = 0.03) and benzodiazepines were associated with lower EQ-5D-5L scores (− 0.059
(0.024), p = 0.01). Participants residing in facilities which had a home-like model of residential care were less likely to
be prescribed psychotropic medications (OR (95% CI): 0.24 (0.12, 0.46), p < 0.001).
Conclusions: An increased number of psychotropic medications were associated with lower quality of life scores.
These medications have many associated adverse effects and the use of these medications should be re-examined
when investigating approaches to improve quality of life for older people in residential care. Home-like models of
residential care may help to reduce the need for psychotropic medications, but further research is needed to
validate these findings.
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Background
In Australia in 2017 365,000 people were estimated to be
living with dementia and almost half of these people were
living in cared accommodation such as residential aged care
facilities [1]. People who live in residential aged care facilities
are more likely to experience a reduced quality of life com-
pared to those living in the community [2]. Although quality
of life does not always decrease as dementia progresses, de-
generation of cognitive function and mood often reduces
quality of life amongst people living with dementia [3].
Psychotropic medications include antipsychotics, anti-
depressants and benzodiazepines and these are com-
monly prescribed to older people in residential settings,
particularly those with dementia, to manage behavioural
and psychological symptoms of dementia (BPSD), des-
pite limited evidence of efficacy in this setting and their
known potential serious adverse effects [4, 5]. Advancing
age and polypharmacy both increase the risk of these ef-
fects [6]. Evidence has suggested these medications may
be over prescribed in residential aged care facilities in
many countries, including Australia [7]. Potentially in-
appropriate use of psychotropic medications is a particu-
lar concern for people living in residential aged care as
psychotropic medications have been associated with in-
creased risk of falls, hospitalization, stroke and mortality
in this population [7].
The physical environment of residential aged care fa-
cilities may affect quality of life for residents [8]. Re-
search has suggested the development of a ‘home-like’
model of care which creates a person-centred environ-
ment and endeavours to facilitate independence for the
residents may improve outcomes for residents, their
family members and staff [9, 10]. These home-like
models aim to provide a familiar environment for the
resident to ease the transition from their family home to
residential care. Establishing the home-like environment
may involve different methods such as providing smaller
living units with only 10 or 15 residents grouped to-
gether, increasing access to outdoor areas, encourage-
ment and support for residents participating in domestic
tasks (such as meal preparation), allocation of staff to
the living unit routinely, home-like furnishings and insti-
tutional ‘presences’ such as medication carts, laundry
trolleys removed or minimised. However, further re-
search is needed to gain a clear understanding of the ef-
fect of home-like models of care on health-related
outcomes of residents [11]. In this study we examined if
there is a difference in the prevalence of psychotropic
medications in residential facilities with a home-like
model of care compared to a standard model of care as
we hypothesized that these person-centred environments
may reduce the need for these medications.
Previous studies have suggested an association be-
tween potentially inappropriate medications and lower
quality of life in older people in residential care [12, 13].
However, there is limited evidence of the effect of the
broad range of psychotropic medications on quality of
life in people residing in aged care facilities with high
levels of cognitive impairment and dementia. The objec-
tives were to examine the association between psycho-
tropic medications and quality of life in the Investigating
Services Provided in the Residential Environment for
Dementia (INSPIRED) study and also to examine if there
was a difference between psychotropic medication use in
a home-like model of residential care compared to a
more standard model of care.
Methods
Study participants
The INSPIRED study is a cross-sectional study of people
living in residential aged care facilities in Australia and
included participants with cognitive impairment and de-
mentia. The study received ethical approval from the
Flinders Social and Behavioural Research Ethics Com-
mittee (Approval numbers 6732 and 6753). Briefly, the
study included 541 long-term permanent residents (re-
sided at the facility for 12 months or more) from 17 dif-
ferent facilities in four different states in Australia and
participants either self-consented to be part of the study
or a proxy (a close family member) provided consent on
their behalf when the participant had moderate to severe
cognitive impairment (PAS-Cog score ≥ 10). Further
details of the INSPIRED study have been reported
elsewhere [14].
Measurement of medication use
Retrospective pharmacy dispensing records from the
100 days prior to the study start date for their facility
were used to determine medication use. Recent prescrip-
tion of a psychotropic medication referred to dispensing
of the medication in the 100 day period. However, 3.5%
(n = 19) of the participants had missing pharmacy re-
cords and therefore reviews of their medication charts
were undertaken instead. No medication data were avail-
able for four of the participants, so the total sample size
was 537 (99.3%). Psychotropic medications were defined
based on a list of psychotropic medications from the
Australian Medicines Handbook [15]. The medications
were further classified in to three groups: antipsychotics,
antidepressants and benzodiazepines.
Resident-level characteristics
Data collected from the participants included Psycho-
geriatric Assessment Scale-Cognitive Impairment Scale
(PAS-Cog) scores, modified Barthel Index scores and
Neuropsychiatric Inventory (NPI) scores. To assess qual-
ity of life, a dementia specific measure of health-related
quality of life was applied: the DEMQOL (self-completed
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by the participant) and the DEMQOL-Proxy (completed
by a proxy for the participant). The DEMQOL is the
only dementia specific quality of life instrument cur-
rently to have a set of utility weights developed, allowing
it to be applied in cost-utility studies for evaluating the
economic effectiveness of health and care interventions
[16, 17]. Utility scores for the DEMQOL and DEMQOL-
Proxy were then generated by applying preference-
weights generated from the valuation study [17]. A
measure of generic health-related quality of life (the EQ-
5D-5L) was also undertaken (self-completion or proxy)
[18]. Utility scores for the EQ-5D-5L were generated
using preference-weights from a previous study [19].
The EQ-5D is the most commonly used quality of life
scale in health research and as a generic preference
based measure of quality of life it can be validly applied
across participant groups and intervention types. The
EQ-5D has been extensively studied and has been shown
to have excellent reliability and validity, while the new 5
level version (as used in the current study) has been
shown to reduce ceiling effects seen in people with
minor health related quality of life impairments [18, 20].
Facility-level characteristics
Data collected regarding the residential aged care facility
included information from a standardised questionnaire
(previously validated in a residential aged care popula-
tion [21]). The questionnaire covers general characteris-
tics, the living and care concept, living-unit staffing and
the physical environment.
A home-like model of residential care in the INSPIRED
study
The INSPIRED study includes some facilities which have
adopted a small group home-like environment of resi-
dential care. In the INSPIRED study, these home-like fa-
cilities were identified if the living units had five or more
of six characteristics including smaller size (up to 15 res-
idents), independent access to outdoors, care staff allo-
cated to living units, meals cooked in the living units,
self-service option for meals and residents given the op-
tion to assist with meal preparation [22, 23]. Further de-
tails of how these criteria were developed have been
described elsewhere [24].
Statistical analysis
The data had a two-level hierarchal structure as the resi-
dents were clustered in residential aged care facilities.
Multi-level linear models were used to test for associa-
tions between psychotropic medication use and continu-
ous test scores (quality of life measures, PAS-Cog scores
and NPI scores). Logistic regression models were used
to examine associations with a home-like model of care.
Models were adjusted for potential confounding factors:
facility-level characteristics (model of care: home-like or
standard, location, number of direct care hours per resi-
dent, facility costs per resident and size of facility) and
resident-level characteristics (age, sex, marital status,
PAS-Cog scores, number of co-morbid conditions, NPI
scores, social ties and activities of daily living). P < 0.05
was regarded as statistically significant. All analyses were
completed using Stata v.14.0 (Stata Corp LP, College
Station, TX, USA).
Results
Characteristics of the participants
The mean (SD) age of the participants was 85.5 (8.5)
years old and 74.5% (n = 403) were female (Table 1).
These figures are comparable with characteristics of
those residing in permanent aged care in Australia,
where the average age is 84.5 years old and 69% are fe-
male [25]. The median (IQR) PAS-Cog score of the par-
ticipants was 15 (6–21) and a dementia diagnosis was
recorded for 64.3% (n = 348) of the participants. This is
higher than for the permanent aged care population of
Australia, where 52% of the population have a diagnosis
of dementia. Of the participants involved, 83% (n = 448)
had some reported level of cognitive impairment, ran-
ging from mild to severe.
Table 1 Characteristics of the participants of the INSPIRED Study
Characteristic All participants
(n = 541)
Participants residing in a
home-like model of care (n = 120)
Participants residing in a standard
model of care (n = 421)
P value
Participant characteristics
Age, mean (SD) 85.5 (8.5) 83.3 (9.0) 86.1 (8.3) 0.001
Female, n (%) 403 (74.5) 90 (75.0) 313 (74.4) 0.89
Married, n (%) 137 (25.4) 36 (30.0) 101 (24.1) 0.19
Barthel Index, median (IQR) 35 (9–71) 34 (5–66) 36 (11–72) 0.18
NPI, median (IQR) 7 (3–12) 10 (6–15) 6 (3–12) < 0.001
PAS-Cog, median (IQR) 15 (6–21) 21 (15–21) 12 (4–21) < 0.001
Number of co-morbid conditions, mean (SD) 3.7 (1.4) 3.2 (1.4) 3.8 (1.4) < 0.001
Abbreviations: IQR Inter-quartile range, P values are from chi-squared or Mann-Whitney tests
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Psychotropic medication use amongst the participants
There were 380 participants (70.8%) who had been pre-
scribed/dispensed one or more psychotropic medications
in the 100 days prior to the study start date. The number
of psychotropic medications a person was exposed to
ranged from 0 to 5 psychotropic medications. The me-
dian (IQR) total number of different medications (regu-
lar and as needed, prescription and over the counter)
that participants were prescribed was 10 (7–13), of
which 10.0% (0%–18.8%) were psychotropic medications.
For the individual classes of psychotropic medications,
the following prevalence rates were observed: anti-
depressant 49.9% (n = 268), antipsychotic 24.8% (n = 133)
and benzodiazepine 30.5% (n = 164). A list of the differ-
ent psychotropic medications prescribed to the partici-
pants is shown in the Additional file 1: Table S1.
Psychotropic medications and a home-like model of
residential care
Of the 17 facilities which participated, 4 facilities (23.5%)
were classified as a home-like model of residential care
(22.2% (n = 120) residents living in a home-like model
and 77.8% (n = 421) residents living in a standard
model). Of those who resided in a home-like model of
care, 98.3% (n = 118) had a diagnosis of dementia. Partic-
ipants residing in a home-like model of care were youn-
ger, had higher NPI scores, had higher (worse) PAS-Cog
scores and had fewer co-morbid conditions than those
living in a standard model of residential care (p < 0.05)
(Table 1).
The proportion of people taking a psychotropic medi-
cation in a home-like model was 61.7% and residents
were significantly less likely to be taking a psychotropic
medication in a home-like model compared to those in a
‘standard model’ (OR (95% CI) 0.24 (0.12, 0.46), p < 0.001),
after adjustments (Table 2). These participants were also
less likely to be taking antidepressants (0.50 (0.28,
0.88), p = 0.02) and benzodiazepines (0.11 (0.05, 0.24),
p < 0.001).
Psychotropic medications and quality of life
The use of psychotropic medications was not associated
with quality of life according to any of the quality of life
measures, but an increasing number of psychotropic
prescriptions was associated with significantly lower
EQ-5D-5L scores (β (SE) after adjustment for potential
confounding factors: − 0.024 (0.011), p = 0.03) and sig-
nificantly lower DEMQOL-Proxy-Utility scores (− 0.012
(0.006), p = 0.04) (Table 3).
When examining the DEMQOL self-report scores
(n = 228), psychotropic medications (− 0.024 (0.017),
p = 0.16) and an increasing number of psychotropic
medications (− 0.009 (0.009), p = 0.32) were not asso-
ciated with lower quality of life after adjusting for
confounding factors.
Different classes of psychotropic medications and quality
of life
When looking at the psychotropic medications by differ-
ent classes of drugs, antipsychotic medications and ben-
zodiazepines were associated with some measures of
reduced quality of life. Antipsychotic medications were
associated with lower DEMQOL-Proxy-Utility scores
after adjustment for confounding factors (− 0.030 (0.014),
p = 0.03). Benzodiazepines were associated with reduced
quality of life according to the EQ-5D-5L (− 0.059 (0.024),
p = 0.01).
Discussion
In this cross-sectional study of older adults with high
levels of cognitive impairment and dementia, living in
Australian residential care facilities, higher exposure to
psychotropic medications was associated with lower
quality of life. Antipsychotics and benzodiazepines were
both independently associated with lower quality of life.
In facilities which had adopted a small group home-like
model of residential care, there was a lower prevalence
of psychotropic medications.
In this study, 24.8% of the total population and 35.9%
of the population with a diagnosis of dementia had been
prescribed an antipsychotic recently. This is in line with
rates of antipsychotic medications reported previously in
Australian residential aged care facilities which have
shown prevalence rates of antipsychotics of 30.2% [26]
for all residents, and 28.2% [27] to 44% [28] for residents
with dementia. The rate for benzodiazepines (30.5%) was
similar for those with or without a diagnosis of dementia
and this is higher than in previous studies of residential
aged care facilities in Australia: 11.4% for all residents
[26] and 18.8% in residents with dementia [27]. Resi-
dents living in facilities which had adopted a home-like
model of residential care were less likely to be prescribed
benzodiazepines and antidepressants. Further research
should investigate how these facilities are managing to
Table 2 Psychotropic medications in a home-like model of
residential care compared with standard models of care
Home-like model, OR (95% CI), P value
Psychotropic medication 0.24 (0.12, 0.46), < 0.001
Antipsychotic medication 0.67 (0.34, 1.33), 0.25
Antidepressant medication 0.50 (0.28, 0.88), 0.02
Benzodiazepine medication 0.11 (0.05, 0.24), < 0.001
The reference for prescribed one or more psychotropic medications is being
prescribed no psychotropic medications. The models are adjusted for facility-
level confounding factors: location, number of direct care hours, facility cost
and size of facility and resident-level characteristics: age, sex, marital status,
PAS-Cog scores, number of co-morbid conditions, NPI scores, social ties and
Barthel Index
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limit the use of benzodiazepines and antidepressants,
despite the high proportion of people residing in these
facilities with dementia.
Psychotropic medications can have many adverse ef-
fects including cardiovascular complications and adverse
mental state changes [15]. Recommendations have been
made to avoid the use of certain medications in older
people and people with dementia, including antipsy-
chotics and benzodiazepines [29]. However, people with
dementia are very likely to experience BPSD at some
point and this can be a significant challenge for staff in
residential care [30]. Recent clinical practice guidelines
for people with dementia suggest non-pharmacological
interventions should be used as a first line treatment for
changed behaviours, such as person-centred care ap-
proaches, individual care plans and specific therapies
[31]. Despite such recommendations, previous studies
have suggested there may be inappropriate prescribing
of psychotropic medications [32]. As demonstrated in
this study, psychotropic medications may be associated
with lower quality of life. People who were prescribed a
psychotropic medication also had higher levels of neuro-
psychiatric problems and cognitive impairment. Those
taking psychotropic medications may have lower quality
of life due to their behavioural symptoms and the results
here may highlight that the current pharmacological
treatments are not managing their behavioural symp-
toms effectively.
Facilities which had adopted a home-like model of
residential care were shown to have a lower prevalence
of psychotropic medications even though the residents
of these facilities were more likely to have dementia,
cognitive impairment and higher NPI scores. However,
individuals residing in a home-like model were also
more likely to be younger and have fewer co-morbid
conditions. Nevertheless, these characteristics were ad-
justed for and therefore these are unlikely to have influ-
enced the results of this study. Home-like small group
models of care in different countries, such as the Green
House model in the US, may improve certain outcomes
for residents such as quality of life, behavioural symp-
toms and well-being [9, 33]. In Europe, research has sug-
gested these home-like models of residential care for
people with dementia may improve physical functioning
of the residents [11]. However, the effectiveness of small
group home-like models on different health-related out-
comes for residents needs to be further explored [11].
The person-centred home-like environment provided in
a home-like model compared to a standard model of
care may be impacting on their management of BPSD,
which may be reducing the use of psychotropic medica-
tions, but this would need to be further explored. Spe-
cific aspects of the home-like model which may be
reducing the need for psychotropic medications could
be the home-like environment is more familiar, being
similar to their family home, that staff assigned to the
living unit may be better equipped to respond to the
challenges seen with people with BPSD without the need
for psychotropic medications, or the home-like model is
a more stimulating environment and is better for the
resident (e.g., increased outdoor access and option to
help with meal preparation). The exact reasons for why
the home-like model may be associated with a lower
prevalence of psychotropic medications would be a
Table 3 Associations between psychotropic medication use and quality of life, cognitive function and behaviour
Psychotropic
medication, β (SE),
P value
Increasing number of
psychotropic medications
β (SE), P value
Antipsychotic
medication, β (SE),
P value
Antidepressant
medication, β (SE),
P value
Benzodiazepine
medication, β (SE),
P value
Quality of life
DEMQOL proxy scores
(n = 535)
−0.020 (0.013), 0.10 −0.012 (0.006), 0.04 − 0.030 (0.014), 0.03 − 0.018 (0.011), 0.11 − 0.008 (0.013), 0.53
DEMQOL scores of the
residents (n = 228)
− 0.024 (0.017), 0.16 − 0.009 (0.009), 0.32 −0.040 (0.025), 0.11 − 0.009 (0.017), 0.61 −0.016 (0.018), 0.37
EQ-5D-5L scores
(resident or proxy)
(n = 531)
−0.018 (0.023), 0.44 −0.024 (0.011), 0.03 − 0.031 (0.026), 0.22 0.003 (0.021), 0.88 − 0.059 (0.024), 0.01
Behaviour
NPI (n = 534) 1.571 (0.506), 0.002 1.072 (0.229), < 0.001 2.525 (0.541), < 0.001 0.495 (0.463), 0.29 1.443 (0.514), 0.005
Cognitive function
PASCog (n = 537) 0.979 (0.577), 0.09 0.752 (0.261), 0.004 2.650 (0.584), < 0.001 −0.401 (0.499), 0.42 −0.136 (0.560), 0.81
The reference for prescribed one or more psychotropic medications is being prescribed no psychotropic medications. The number of psychotropic medications
was analysed as a continuous score. The models are adjusted for facility-level confounding factors: model of care, location, number of direct care hours, facility
cost and size of facility and resident-level characteristics: age, sex, marital status, PAS-Cog scores (except where the outcome is PASCog scores), number of
co-morbid conditions, NPI scores (except where the outcome is NPI scores), social ties and Barthel Index
Abbreviations: DEMQOL Dementia quality of life questionnaire, EQ-5D-5L EuroQol five dimensions questionnaire, NPI neuropsychiatric inventory, PASCog
Psychogeriatric Assessment Scales – Cognition
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useful question for further research in order to improve
the evidence-base to guide management approaches in
residential care.
The prescriptions of psychotropic medications to older
residents in residential aged care facilities need frequent
review to see if the potential harms, which our study sug-
gests may include reduced quality of life, are outweighing
the benefits of the medications and if alternative non-
pharmacological approaches could be used. Functional-
analysis based interventions have been shown to have a
significant effect on reducing global BPSD with moderate
quality evidence and without the adverse events seen with
psychotropic medications [34].
Strengths
Although cross-sectional in nature, this is a relatively
large cohort study in this context, and by including
those who could not consent for themselves we were
able to include people with moderate to severe demen-
tia. Data were collected not only for the residents, but
also for the facilities in which they resided and there was
minimal missing data for the participants. This allowed
for adjustment of a wide-range of potential confounding
factors relating to both the resident and their residential
facility. Furthermore, to assess quality of life we used
two different validated scales, including a dementia spe-
cific health-related quality of life questionnaire (the
DEMQOL) and a generic health-related quality of life
questionnaire (the EQ-5D-5L) which capture distinct as-
pects of health-related quality of life in residential aged
care [35]. Upon comparing the included population with
the national statistics for people residing in permanent
aged care in Australia [25], we found the included popu-
lation had a similar average age and proportion of fe-
males, but there was a slightly higher proportion of
people with a diagnosis of dementia in this study.
Limitations
The facilities which demonstrated a home-like model of
care described in this study were all from the same state
in Australia, operated by the same provider and are
more likely to include people with dementia and poten-
tially more severe behavioural problems. However, in
Australia admission to residential aged care facilities is
often based on availability at the time of need. Further-
more, 40% of eligible participants declined to participate
in the study and therefore the sample may not fully rep-
resent the eligible population. We have limited any bias
by controlling for confounding factors. Also, all of the
recruited organisations were not-for-profit aged care
providers.
As a high proportion of people in the study had mod-
erate to severe cognitive impairment proxy measures
were used. Although self-assessment is preferable where
possible, proxy measures of quality of life are a practical
option in residential aged care [35], however, proxy bias
may be a factor in this study. The facility-level question-
naire has not been previously validated in an Australian
setting and therefore there is further potential for infor-
mation bias. This is a longer questionnaire and although
this was completed by the research assistants hired by
the study, not the participants, bias may be introduced
as the respondent’s fatigue. Furthermore, the gold stand-
ard for measuring medications administered to residents
in aged care facilities would be data collected from medi-
cation charts, rather than dispensing data; however, it was
not feasible to collect this data for all participants in this
study. Due to the cross-sectional nature of the data, we
cannot assess causality and the direction of association.
Therefore, the lower quality of life seen in this study
amongst those taking psychotropic medications may be
leading to the prescriptions of the medications rather than
the medications causing the lower quality of life.
Conclusions
Older people often report that optimal quality of life is a
major priority. Psychotropic medications were associated
with lower quality of life in this study. Health care prac-
titioners and consumers should consider this association,
and the existing evidence of harm vs benefit of psycho-
tropic medicines, when treating older people living in
residential aged care facilities. Adoption of a home-like
environment model for residential care may help to re-
duce the need for psychotropic medications, but this
would need to be further explored.
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defined according to the Australian Medicines Handbook, prescribed to
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